Drug intelligence / Profile preview

HAC2-443

Development stage: Unknown
Lead developer: Huons
Modality: Small Molecules

Overview

HAC2-443 is a small molecule therapeutic candidate being developed by Huons, a South Korean pharmaceutical company, for the treatment of hypertension (high blood pressure) and obesity. Currently in Phase 1 clinical development, it is classified as either a New Chemical Entity (NCE) or an Incrementally Modified Drug (IMD). The drug is designed to address metabolic and cardiovascular comorbidities, though its specific molecular target and mechanism of action have not been publicly disclosed in the company's pipeline documentation.

Beyond the preview

Go deeper on HAC2-443.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAC2-443.

Explore the full profile